Roche's Ocrevus racks up more positive MS data in relapsing and primary progressive forms

23rd June 2017 Uncategorised 0

The positive data for Roche’s Ocrevus keep on coming. Friday, the company’s Genentech unit announced that the multiple-sclerosis fighter had significantly cut down disease activity and disability progression in patients with relapsing forms of the disease and those with the harder-to-treat, primary progressive forms.

More: Roche's Ocrevus racks up more positive MS data in relapsing and primary progressive forms
Source: fierce